BACKGROUND: Allogeneic hematopoietic cell transplantation (HCT) offers curative potential to a number of older patients with acute myeloid leukemia (AML) in their first complete remission. However, there are limited data in the literature concerning post-HCT outcomes for older patients in their second complete remission (CR2). METHODS: The purpose of the current study was to retrospectively investigate within the Center for International Blood and Marrow Transplant Research database parameters influencing posttransplant outcomes for patients 60 years of age or older undergoing HCT for AML in CR2. RESULTS: In total, 196 patients from 78 centers were identified; the median age was 64 years (range, 60-78 years). Seventy-one percent had a Karnofsky performance status 90 at the time of HCT. Reduced-intensity conditioning regimens were used in 159 patients (81%). A univariate analysis demonstrated a 3-year overall survival (OS) rate of 42% (95% confidence interval [CI], 35%-49%), a leukemia-free survival rate of 37% (95% CI, 30%-44%), a cumulative incidence of nonrelapse mortality of 25% (95% CI, 19%-32%), and a cumulative incidence of relapse (CIR) of 38% (95% CI, 31%-45%). A multivariate analysis demonstrated that cytogenetic risk was the only independent risk factor for OS (P 5.023) with a hazard ratio (HR) of 1.14 (95% CI, 0.59-2.19) for intermediate-risk cytogenetics and an HR of 2.32 (95% CI, 1.05-5.14) for unfavorable-risk cytogenetics. For CIR, cytogenetic risk was also the only independent prognostic factor (P 5.01) with an HR of 1.10 (95% CI, 0.47-2.56) for intermediate-risk cytogenetics and an HR of 2.98 (95% CI, 1.11-8.00) for unfavorable-risk cytogenetics. CONCLUSIONS: Allogeneic HCT is a curative treatment option for older patients with AML in CR2, particularly for those with favorable or intermediate cytogenetic risk.
INTRODUCTION
The prognosis of patients with acute myeloid leukemia (AML) has improved significantly over the last 2 decades 1 because of improvements in supportive care and the increasing use of allogeneic hematopoietic cell transplantation (HCT). [2] [3] [4] [5] The introduction of reduced-intensity conditioning (RIC) has enabled older patients to overcome early nonrelapse mortality (NRM), and several studies have reported post-HCT overall survival (OS) rates with RIC or nonmyeloablative conditioning in the range of 30% to 35% at 2 to 3 years when patients undergo transplantation in their first complete remission (CR1). [6] [7] [8] [9] [10] Data on outcomes of patients undergoing HCT in their second complete remission (CR2) are quite limited and are largely derived from case series including a minority of patients undergoing transplantation in CR2. [11] [12] [13] For older patients in particular, some studies have demonstrated a lack of significant effect of patient age on outcomes. 14, 15 Another study has demonstrated that select older patients with a low comorbidity score benefit from allogeneic HCT; however, the majority of that study's patients with AML underwent HCT in CR1. 16 Burnett et al 17 demonstrated the benefit of allogeneic HCT in CR2 for patients with intermediate-and high-risk cytogenetics; however, the median age of that cohort was 38 years. Krauter et al 18 investigated outcomes for patients who were both elderly and had advanced disease, and they demonstrated poor outcomes, although the cohort size was relatively small. Recently, Michelis et al 19 demonstrated that within a small subset of patients 60 years of age or older who were in CR2 at transplant, there were no survivors at 4 years. 19 The identification of older patients with AML in CR2 who could benefit from HCT as well as patients for whom transplantation is likely to be futile is significant. The large size of the Center for International Blood and Marrow Transplant Research (CIBMTR) registry provides an opportunity to study the prognostic factors influencing outcomes. The purpose of the current study was to investigate retrospectively within the CIBMTR database parameters that influence posttransplant outcomes for patients 60 years of age or older undergoing HCT for AML in CR2.
MATERIALS AND METHODS

Data Source
The CIBMTR is a research collaboration between the National Marrow Donor Program/Be the Match Registry and the Medical College of Wisconsin. It comprises more than 450 transplant centers worldwide that contribute detailed data on HCT. Studies conducted by the CIBMTR are performed in compliance with all applicable federal regulations pertaining to the protection of human research participants. Protected health information used in research is collected and maintained in CIBMTR's capacity as a public health authority under the Health Insurance Portability and Accountability Act privacy rule.
The CIBMTR collects data, which include the following: age, sex, disease type, pretransplant disease stage, date of diagnosis, graft type, conditioning regimen, posttransplant disease progression and survival, development of a new malignancy, and cause of death. Data are collected before transplantation, 100 days and 6 months after transplantation, and annually thereafter or until death. The study protocol received a priori approval by the appropriate institutional review committee.
Study Population
The study population identified with the CIBMTR database included patients who underwent allogeneic HCT between 2001 and 2012. A total of 196 patients (from 78 centers) who were 60 years of age or older and underwent allogeneic HCT for AML for the first time in CR2 were identified. Donors were matched sibling donors (MSDs) or unrelated donors (URDs). Patients who had acute promyelocytic leukemia or had previously undergone allogeneic transplantation were excluded. Patients who underwent syngeneic, cord-blood, or haploidentical transplantation were excluded because of the small numbers of older patients in the registry undergoing transplantation in CR2. Patients who received non-calcineurin inhibitor-based graft-versus-host disease (GVHD) prophylaxis or underwent ex vivo T-cell depletion were also excluded.
Variables Included in the Analysis
The data analysis included patient-related variables such as the age at HCT, sex, and Karnofsky performance status (KPS). Disease-related variables included the subtype of AML (de novo vs secondary), the duration of CR1 (in months), and the cytogenetic risk defined according to the Southwest Oncology Group/Eastern Cooperative Oncology Group 20 and modified European Leukemia Net criteria. 21 The CIBMTR classifies cytogenetic risk on the basis of available cytogenetic findings at diagnosis and at HCT (cytogenetics at relapse before HCT are not documented). Molecular abnormalities such as NPM1 and FLT3 have not been documented for the majority of patients in the registry and, therefore, were not included in the analysis. Transplant-related variables included the conditioning regimen intensity (as defined by the CIBMTR), 22 the donor type (MSD, well-matched URD, or partially matched URD), 23 the cytomegalovirus serostatus of the donor and the recipient, the graft source (peripheral blood stem cells vs bone marrow), the type of GVHD prophylaxis, the use of in vivo T-cell depletion, and the time period in which the transplant was performed (2001-2007 vs 2008-2012) .
For remission status-related variables in particular, the CIBMTR defines complete remission as meeting the following criteria: less than 5% blasts in the bone marrow, no blasts with Auer rods, normal maturation of all cellular components in the bone marrow, absence of extramedullary disease, neutrophil count 1000/mL, platelet count 100,000/mL, and transfusion independence. 24 Study Endpoints and Statistical Analysis OS after HCT was the primary endpoint for this study; it was defined as the time from transplantation to death, with surviving patients censored at the last time they were reported to be alive. Leukemia-free survival (LFS) was defined as the time from transplantation to death or relapse, with surviving patients censored at the last time they were reported to be alive and leukemia-free. NRM was defined as death without evidence of leukemia recurrence.
Descriptive statistics were calculated for all variables. A univariate analysis was performed with the KaplanMeier method to calculate OS and LFS, whereas NRM and the cumulative incidence of relapse (CIR) were calculated with the cumulative incidence method with consideration of competing risks. 25 The cumulative incidence method was also used to calculate the time to onset of grade II to IV or grade III to IV acute graft-versus-host disease (aGVHD) according to the Glucksburg criteria 26 100 days after HCT as well as chronic graft-versus-host disease (cGVHD) 3 years after HCT with death in the absence of GVHD as a competing risk.
A multivariate analysis was performed with a Cox proportional hazards model for OS, LFS, CIR, NRM, aGVHD, and cGVHD. The assumption of proportional hazards for each factor in the Cox model was tested with time-dependent covariates. A backward stepwise model selection approach was used to identify significant risk factors, with factors significant at a level of P < .05 kept in the final model.
RESULTS
Patient Characteristics
In total, 196 patients with AML in CR2 met the eligibility criteria. Patient characteristics are outlined in Table 1 . The median follow-up for the survivors was 73 months (range, 6-123 months). The median age at transplant was 64 years (range, 60-78 years), and 81 patients (41%) were female. Seventy-one percent had a KPS 90. De novo AML was diagnosed in 147 patients (75%); among the 49 patients with secondary AML (25%), 41 (21%) were transformed from myelodysplastic syndrome, and 8 (4%) were therapy-linked. As for the duration of CR1, 48 patients (24%) were in CR1 for < 6 months, 48 patients (24%) were for 6 to 12 months, and 74 patients (38%) were for > 12 months; data were missing for 26 (13%). Myeloablative conditioning regimens were used for 37 As for the association of the duration of CR1 with cytogenetic risk, unfavorable-risk cytogenetics were predominant in the group in CR1 for < 6 months (47% of the patients in that subgroup).
OS
In the univariate analysis, we observed a 3-year OS of 42% (95% confidence interval [CI], 35%-49%; Fig. 1 and Table 2 ). The stratification of OS by the cytogenetic risk category is demonstrated in Figure 2 (P 5 .023). In the multivariate analysis ( 
LFS
The univariate analysis demonstrated a 3-year LFS rate of 37% (95% CI, 30%-44%; Fig. 1 and Table 2 ). In the multivariate analysis, we observed that cytogenetic risk (HR for unfavorable risk, 2.92; P 5 .005) and a bone marrow graft source (HR, 1.70; 95% CI, 1.05-2.74; P 5 .03) were significant (Table 3) .
CIR and NRM
The univariate analysis demonstrated 3-year CIR and NRM rates of 38% (95% CI, 31%-45%) and 25% (95% CI, 19%-32%), respectively ( Fig. 3 and Table 2 ). Univariate stratification of CIR by the cytogenetic risk category is shown in Figure 4 Table 3 ).
Cumulative Incidence of aGVHD and cGVHD
In the univariate analysis, the cumulative incidence of grade II to IV aGVHD at 100 days was 33% (95% CI, 26%-40%), whereas the cGVHD rate at 3 years was 54% (95% CI, 46%-61%; Table 2 ). Among the 99 patients with cGVHD, 21 were limited and 78 were extensive according to the Seattle criteria. 27 The multivariate analysis for cGVHD demonstrated an increased incidence with secondary/therapy-related AML (HR, 2.30; 95% CI, 1.43-3.71; P 5 .001) and an absence of in vivo T-cell depletion (HR, 2.33; 95% CI, 1.43-3.80; P 5 .001), whereas MSD transplants were associated with less cGVHD (HR, 0.37; 95% CI, 0.21-0.66; P 5 .001). The multivariate analysis for aGVHD did not demonstrate any independent prognostic factors among the variables analyzed.
Cause of Death
In the time span involving the study, 133 patients died, and the causes of death are summarized in Table 4 . Most deaths were related to disease relapse (61 patients or 46%). Infection was the primary cause in 19 patients (14%), GVHD was the primary cause in 15 patients (11%), and organ failure was the primary cause in 13 patients (10%).
DISCUSSION
In the current retrospective registry analysis, we have demonstrated that for AML patients 60 years of age or older in CR2, HCT is a curative treatment option with a 3-year OS of 42%. We have also demonstrated that the cytogenetic risk category of AML is an independent risk factor for LFS and is the only independent risk factor for OS and CIR. The weight of this increased risk is carried by unfavorable cytogenetic risk, with patients in that category demonstrating a 3-fold increase in the risk of relapse after HCT. These results are in contrast to a recent publication from the Princess Margaret Cancer Centre in Toronto, Canada, where outcomes were analyzed for 242 patients who underwent HCT for AML; 16 were 60 years old or older and in CR2. 19 The OS rate at 3 years was 39% and 16% for patients 60 years old or older in CR1 and CR2, respectively, whereas no survivors were observed in the 60-year CR2 group 4 years after HCT.
In another publication from the same center examining risk factors for the outcome of HCT for patients of all ages with AML in CR2, 28 older age was associated with inferior OS as well as a brief duration of CR1 and a high HCT comorbidity index. In the current study, which was limited to patients 60 years old or older, the duration of CR1 did not demonstrate an independent prognostic significance for any of the outcomes; however, this could be related to the correlation of the brief duration of CR1 with adverse cytogenetic risk, 29 which in our analysis was the dominant variable determining survival and relapse. In the current data set, almost half of the unfavorable cytogenetic risk patients demonstrated a CR1 duration < 6 months.
The negative influence of unfavorable-risk cytogenetics on a small number of older patients undergoing transplantation in CR2 has been demonstrated in previous work from Armistead et al, 11 who found no survival advantage with HCT versus chemotherapy alone, both treatments being associated with a median survival time of 5 months. On the other hand, Kurosawa et al 15 demonstrated that there was similar survival for both intermediate-and unfavorable-risk cytogenetic groups undergoing HCT in CR2; however, these patients were younger than those in our study. In the current cohort of older patients, those with an unfavorable risk demonstrated a 3-year survival rate of 25% and a CIR of almost 70%. The survival rate of that subgroup did not plateau with further followup (Fig. 2) , with relapse being the predominant cause of death.
The current study demonstrated certain limitations, such as a lack of sufficient data reflecting the quality of life of these patients after HCT because only two-thirds of the patients alive at last follow-up had a documented KPS. A significant limitation was the relatively small size of the cohort, which may have limited the potential of the analysis to detect significant differences regarding certain important parameters. For instance, we had 15% power to detect the observed 5-year survival difference between conditioning intensity groups (myeloablative conditioning vs RIC) but only 10% power for the detection of the observed 5-year survival difference between sibling and well-matched URD groups and even less power to detect observed differences between the other donor subgroups. For in vivo T-cell depletion, we had only 16% power to detect the observed 5-year difference (notably, 38% of patients receiving unrelated transplants underwent in vivo T-cell depletion, whereas 12% of patients receiving related transplants did).
Another significant limitation was the fact that the CIBMTR database does not currently provide sufficient data concerning minimal residual disease before transplantation, the impact of which could not be assessed in this study. Moreover, molecular markers such as NPM1 and FLT3, which could help to stratify the large intermediate cytogenetic risk category into prognostic groups, were not available for most patients in this study. Planned revisions in the CIBMTR data collection forms will include additional parameters such as those described previously. Finally, one must consider the inherent bias in assessing the results of allogeneic HCT in CR2 for older patients because these patients represent the select minority that achieve CR2 and are physically fit enough to undergo HCT. 30 In conclusion, this study has demonstrated the potential for long-term remission with allogeneic HCT in select older patients with AML in CR2. However, patients with adverse cytogenetic risk derive a very limited benefit from transplantation despite achieving CR2. The large size of the CIBMTR registry has provided an opportunity to investigate potential prognostic factors in a wellpowered study. On the basis of the current findings, older patients in CR2 may potentially benefit from novel posttransplant interventions aimed predominantly at reducing the risk of relapse. These patients should be offered thorough counseling concerning the risk of transplant-related morbidities and mortality.
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